43 / 85
ADT + AA + P Mejora significativa fatiga (astenia)
0.4
0.2
0.0
-0.2
-0.4
Cycle*
ADT + Placebos
ADT + AA + P
Mean change from baseline
in worst fatigue score (BFI)
7 9
5
3
0
15 17
21
19
23 25 27 29 31 33
2 4 6 8
11 13
10 12
1
Worse
Better
0
465
407
372
259
305
171
216
106
46
44
14
2
1
6
12
18
24
30
36
42
HR 0.65 (95% CI, 0.53-0.81)
P
= 0.0001
ADT + AA + P, NR
ADT + Placebos, NR
Months
118
Patients without worst
fatigue progression (%)
100
80
60
20
0
40
597
602
Patients at risk
ADT + AA + P
ADT + Placebos
35% Risk Reduction
for Worst Fatigue Progression
Mean Change From Baseline
Differed from Cycle 5 Onward
*1 cycle = 28 days.
Chi K, ESMO 2017